Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025. Additionally, Enveric will attend Biotech Showcase 2025 from January 13-15, 2025. Both conferences are being held in San Francisco during “J.P. Morgan Week 2025.”
During the events, members of Enveric’s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Details are as follows:
| Event: | Sachs Associates 8th Annual Neuroscience Innovation Forum |
| Panel: | Future of Psychedelics – January 12, 2025, at 2:20 p.m., PT |
| Presentation: | 4:05 p.m., PT, January 12, 2025 – Track E – Room Heritage |
| Location: | Marines’ Memorial Club |
| Registration: | https://www.sachsforum.com/8nif-registration.html |
| Event: | Biotech Showcase 2025 |
| Date and Time: | January 13-15, 2025 |
| Location: | Hilton San Francisco Union Square |
| Registration: | https://informaconnect.com/biotech-showcase/registration-options/ |
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, Psybrary™, Enveric has created a robust intellectual property portfolio of new chemical entities for specific mental health indications. Enveric’s lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.